Key points
- Record FY26 revenue of $60.3 million, up 18.5% from FY25
- EBITDA increased by 72.1% to $5.4 million
- Operating cash inflow of $6.6 million; cash improved to $5.6 million
- SaaS revenue up 70% to $10.2 million
- Delivered $2 million cost savings program
Full summary
Compumedics Limited (ASX: CMP) reported its FY26 results, showcasing significant financial growth. The company achieved record revenue of $60.3 million, a 18.5% increase from the previous year. EBITDA rose by 72.1% to $5.4 million, with an EBITDA margin of approximately 9%. The company also reported a net operating cash inflow of $6.6 million, resulting in a cash position of $5.6 million. SaaS revenue from Somfit and Nexus 360 increased by 70% to $10.2 million, highlighting growth in recurring, software-enabled revenue. MEG contributed $9.7 million of FY26 revenue, with approximately $13.1 million of MEG open orders entering FY27. Compumedics also delivered a $2 million cost savings program, reflecting tighter cost discipline and organizational efficiencies.
Guidance
FY27 revenue growth expected to be double-digit; EBITDA growth faster than revenue
Outlook
Compumedics targets further double-digit revenue growth in FY27, supported by order book conversion, MEG activity, and growth in recurring revenues. The company aims for EBITDA growth at a faster rate than revenue.